PURE Bioscience, Inc.
PURE
$0.0653
$0.00538.83%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 391.00K | 556.00K | 474.00K | 441.00K | 326.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 391.00K | 556.00K | 474.00K | 441.00K | 326.00K |
| Cost of Revenue | 164.00K | 231.00K | 199.00K | 183.00K | 149.00K |
| Gross Profit | 227.00K | 325.00K | 275.00K | 258.00K | 177.00K |
| SG&A Expenses | 871.00K | 881.00K | 845.00K | 998.00K | 1.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.12M | 1.18M | 1.11M | 1.26M | 1.29M |
| Operating Income | -725.00K | -627.00K | -639.00K | -817.00K | -964.00K |
| Income Before Tax | -798.00K | -689.00K | -756.00K | -857.00K | -1.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -798.00K | -689.00K | -756.00K | -857.00K | -1.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -798.00K | -689.00K | -756.00K | -857.00K | -1.00M |
| EBIT | -725.00K | -627.00K | -639.00K | -817.00K | -964.00K |
| EBITDA | -724.50K | -590.00K | -601.00K | -781.00K | -927.00K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 111.86M | 111.86M | 111.86M | 111.86M | 111.86M |
| Average Diluted Shares Outstanding | 111.86M | 111.86M | 111.86M | 111.86M | 111.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |